The Big Ten Cancer Research Consortium is pleased to announce Cristina Truica, MD, as a new member of the Big Ten CRC Steering Committee. Dr. Truica is a medical oncologist at Penn State Cancer Institute and has been an active member of the Big Ten CRC breast cancer working group for more than a decade. Read More
Jan 22, 2026 As we look back on the past year, I want to extend my sincere appreciation to our investigators, 16 member institutions, leadership teams, research staff, and partners across the Big Ten Cancer Research Consortium. Read More
A Big Ten CRC study, BTCRC-GI21-500, will be presented as a Trials in Progress poster at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 in San Francisco. This study is led by Ashish Manne, MBBS, of The Ohio State University. Read More
In this month’s Across the Consortium, the Big Ten Cancer Research Consortium highlights the innovation, discovery, and impact happening across our member institutions. From novel therapies to community-focused initiatives, this issue showcases the depth of research that drives progress in cancer prevention, detection, and treatment throughout our member institutions. Read More
A Big Ten Cancer Research Consortium clinical trial, BTCRC-BRE15-024, titled “A phase I/II, single arm, nonrandomized study of ribociclib, a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor inhibitor, in advanced AR-positive triple-negative breast cancer,” (SABCS Poster # PS5-02-26) will be presented by Julia Knight-Shefner, MD, of the University of Wisconsin Carbone Cancer Center, as a poster at the 2025 San Antonio Breast Cancer Symposium. Read More
Nov. 19, 2025 The Big Ten Cancer Research Consortium is pleased to announce William P. Harris, MD, as a new member of the Big Ten CRC Steering Committee. Dr. Harris is a board-certified medical oncologist at Fred Hutchinson Cancer Center and UW Medical Center and serves as an associate professor in the Division of Hematology and Oncology at the University of Washington. Read More
Dec 2, 2025 A Big Ten CRC clinical trial, BTCRC-LUN18-363, titled, “Chemo-immunotherapy followed by durvalumab and ceralasertib in treatment naïve patients with extensive-stage small cell lung cancer,” led by Muhammad Furqan, MD, formerly of the University of Iowa, was featured as a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin. Read More
The Big Ten Cancer Research Consortium is pleased to announce Gustavo Girotto, MD, as a new member of the Big Ten CRC Steering Committee. Dr. Girotto is a Clinical Professor of Internal Medicine in Hematology, Oncology, and Blood and Marrow Transplantation at the University of Iowa Holden Comprehensive Cancer Center. Read More
October 24, 2025: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium highlights examples of discovery and impact from our member institutions. This issue covers a broad range of efforts to advance cancer research and care, from pioneering clinical trials and artificial intelligence diagnostics to novel immunotherapies, personalized treatments, and community-focused initiatives across Big Ten CRC member institutions. Read More
At the 2025 Big Ten Cancer Research Consortium Summit on September 12, investigators from member institutions shared updates on several Big Ten CRC studies. These presentations underscored the collaborative, investigator-initiated work that drives the Big Ten CRC’s mission.
February 3, 2025
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube